NEW INVESTMENT: b-RayZ AG

Convergence Partners has co-lead the oversubscribed CHF 4m Series A financing round of b-RayZ AG, a spin-a spin-off from University Hospital Zurich (USZ) that has commercialised a unique and revolutionary AI-based platform supporting radiologists in the early detection of breast cancer. b-rayZ’s b-box system is already CE-marked and in commercial use in leading breast centers in Europe. Co-lead investors are LifeCare Partners and Protagon AG.

Cristina Rossi, CEO & co-founder of b-rayZ comments: "Our AI technology helps to significantly improve the quality of breast cancer diagnostics by analyzing mammographies in real time. The next generation of products enable automatic detection of early-stage lesions in mammography and ultrasound, that are often missed or misdiagnosed in breast cancer patients. Mikael von Euw, deal lead at Convergence Partners adds: "b-rayZ is going to an emerging leader in the AI-powered cancer imaging diagnostic and workflow SaaS sector. What distinguishes the company from many competitors is the deep clinical background of the company and its exclusive access to a high-quality data. The SaaS platform will enable improved cancer care and contribute to a reduction in costs for diagnosis and therapy".

About b-rayZ

Failing breast cancer diagnoses, because of human errors harm patients, expose doctors to high liability risks, and increase healthcare costs. b-rayZ is transforming breast cancer diagnostics through its AI ground-breaking technology for faster and better diagnoses. b-rayZ’s success is driven by the commitment to save women’s lives with breast cancer early detection. Every woman, everywhere.

For more information, please visit www.b-rayz.ch